

NDA 211280/S-008

SUPPLEMENT APPROVAL

Eli Lilly and Company
Attention: Mitchell R. Cunningham, PharmD
Consultant, Global Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Cunningham:

Please refer to your supplemental new drug application (sNDA) dated and received March 16, 2022, received and your amendments, submitted under section 505(b)/pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Reyvow (Lasmiditan) tablets.

This “Prior Approval” sNDA provides for the following changes to the Reyvow Prescribing Information (PI) based on clinical drug interaction trial final study reports:

- Removal of the recommendation in the Drug Interactions section (7.4) of the PI to avoid concomitant use of Reyvow with drugs that are P-glycoprotein (P-gp) and Breast Cancer Resistant Protein (BCRP) substrates.
- Addition in the Drug Interactions section (7.4) of the PI that coadministration of Reyvow with P-gp substrates where a small change in substrate plasma concentrations may lead to serious toxicities is not recommended.
- Revisions in the Clinical Pharmacology section (12.3) of the PI to reflect information from the completed drug interaction studies.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have received your submission dated March 16, 2022, containing the final reports for the following postmarketing requirements listed in the October 11, 2019, Approval letter.

- 3728-7 Conduct a clinical drug interaction trial to evaluate the effect of Reyvow at its highest approved dose level on the pharmacokinetics of a sensitive Pgp substrate (e.g., digoxin) to address the potential for increased exposure and excessive drug toxicity.
- 3728-8 Conduct a clinical drug interaction trial to evaluate the effect of Reyvow at its highest approved dose level on the pharmacokinetics of a sensitive BCRP substrate (e.g., rosuvastatin) to address the potential for increased exposure and excessive drug toxicity.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

We have reviewed your submission and conclude that the above requirements were fulfilled.

We remind you that there are postmarketing requirements listed in the October 11, 2019, Approval letter that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Daniel Ngembus, Regulatory Project Manager, at (301) 837-7345.

Sincerely,

{See appended electronic signature page}

Nick Kozauer, MD
Director
Division of Neurology 2
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NICHOLAS A KOZAUER
09/15/2022 01:46:26 PM